使用铂类药物的前景

Sadkova Yu.A., Grishina M.G., Pigarev S.E., Fedoros E.I.
{"title":"使用铂类药物的前景","authors":"Sadkova Yu.A., Grishina M.G., Pigarev S.E., Fedoros E.I.","doi":"10.26787/nydha-2686-6838-2023-25-12-43-50","DOIUrl":null,"url":null,"abstract":"The article provides a summary of the biological effects and existing indications for the use of registered platinum compounds. Cisplatin continues to be used to treat a wide range of malignancies, the main ones being lung (49%), testicular (2%), ovarian (7%), uterine cancer (13%), head and neck tumors (16%), and bladder cancer (13%). The results of an analysis of the global market for these drugs and a forecast until 2026, as well as the Russian market for 2022, are presented. The prospects for the development and registration of new drugs and new promising combinations involving drugs from this group are described. Analysis of recommendations from the professional oncology community indicates continued widespread use of existing platinum drugs. There has been a trend towards an increase in global sales, largely due to their increase in the Asia-Pacific region, countries of Central Asia and Africa. On the Russian market, whose capacity is 1.3% and 1.9% of sales of all anticancer drugs in value and volume terms, domestic manufacturers are satisfactorily represented. New promising treatment regimens are being developed, including those that include proprietary drugs (primarily PARB inhibitors); There remains interest in the development of innovative platinum drugs. The summarized information was obtained from official sources of the State Register of Medicines of the Ministry of Health of Russia, the Electronic Rubricator of Clinical Recommendations and Clinical Guidelines and orders on Standards of Medical Care prepared on their basis, and the drug sales database of the marketing agency DSM Group.","PeriodicalId":263577,"journal":{"name":"\"Medical & pharmaceutical journal \"Pulse\"","volume":"111 41","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PROSPECTS FOR THE USE OF PLATINUM DRUGS\",\"authors\":\"Sadkova Yu.A., Grishina M.G., Pigarev S.E., Fedoros E.I.\",\"doi\":\"10.26787/nydha-2686-6838-2023-25-12-43-50\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article provides a summary of the biological effects and existing indications for the use of registered platinum compounds. Cisplatin continues to be used to treat a wide range of malignancies, the main ones being lung (49%), testicular (2%), ovarian (7%), uterine cancer (13%), head and neck tumors (16%), and bladder cancer (13%). The results of an analysis of the global market for these drugs and a forecast until 2026, as well as the Russian market for 2022, are presented. The prospects for the development and registration of new drugs and new promising combinations involving drugs from this group are described. Analysis of recommendations from the professional oncology community indicates continued widespread use of existing platinum drugs. There has been a trend towards an increase in global sales, largely due to their increase in the Asia-Pacific region, countries of Central Asia and Africa. On the Russian market, whose capacity is 1.3% and 1.9% of sales of all anticancer drugs in value and volume terms, domestic manufacturers are satisfactorily represented. New promising treatment regimens are being developed, including those that include proprietary drugs (primarily PARB inhibitors); There remains interest in the development of innovative platinum drugs. The summarized information was obtained from official sources of the State Register of Medicines of the Ministry of Health of Russia, the Electronic Rubricator of Clinical Recommendations and Clinical Guidelines and orders on Standards of Medical Care prepared on their basis, and the drug sales database of the marketing agency DSM Group.\",\"PeriodicalId\":263577,\"journal\":{\"name\":\"\\\"Medical & pharmaceutical journal \\\"Pulse\\\"\",\"volume\":\"111 41\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\\\"Medical & pharmaceutical journal \\\"Pulse\\\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26787/nydha-2686-6838-2023-25-12-43-50\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"\"Medical & pharmaceutical journal \"Pulse\"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26787/nydha-2686-6838-2023-25-12-43-50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

文章概述了注册铂化合物的生物效应和现有适应症。顺铂仍被用于治疗多种恶性肿瘤,主要包括肺癌(49%)、睾丸癌(2%)、卵巢癌(7%)、子宫癌(13%)、头颈部肿瘤(16%)和膀胱癌(13%)。报告对这些药物的全球市场进行了分析,并对 2026 年之前的市场进行了预测,还对 2022 年的俄罗斯市场进行了分析。此外,还介绍了新药的开发和注册前景,以及涉及这类药物的有前景的新组合。对专业肿瘤学界建议的分析表明,现有铂类药物仍在广泛使用。全球销售额呈上升趋势,主要原因是亚太地区、中亚国家和非洲的销售额有所增加。在俄罗斯市场,国内制造商的销售额和销售量分别占所有抗癌药物销售额和销售量的 1.3% 和 1.9%,表现令人满意。目前正在开发新的有前途的治疗方案,包括包括专利药物(主要是 PARB 抑制剂)在内的治疗方案。汇总信息来自俄罗斯卫生部国家药品登记处的官方资料、临床建议和临床指南电子评分器及在此基础上编制的医疗标准指令,以及营销机构帝斯曼集团的药品销售数据库。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PROSPECTS FOR THE USE OF PLATINUM DRUGS
The article provides a summary of the biological effects and existing indications for the use of registered platinum compounds. Cisplatin continues to be used to treat a wide range of malignancies, the main ones being lung (49%), testicular (2%), ovarian (7%), uterine cancer (13%), head and neck tumors (16%), and bladder cancer (13%). The results of an analysis of the global market for these drugs and a forecast until 2026, as well as the Russian market for 2022, are presented. The prospects for the development and registration of new drugs and new promising combinations involving drugs from this group are described. Analysis of recommendations from the professional oncology community indicates continued widespread use of existing platinum drugs. There has been a trend towards an increase in global sales, largely due to their increase in the Asia-Pacific region, countries of Central Asia and Africa. On the Russian market, whose capacity is 1.3% and 1.9% of sales of all anticancer drugs in value and volume terms, domestic manufacturers are satisfactorily represented. New promising treatment regimens are being developed, including those that include proprietary drugs (primarily PARB inhibitors); There remains interest in the development of innovative platinum drugs. The summarized information was obtained from official sources of the State Register of Medicines of the Ministry of Health of Russia, the Electronic Rubricator of Clinical Recommendations and Clinical Guidelines and orders on Standards of Medical Care prepared on their basis, and the drug sales database of the marketing agency DSM Group.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信